RenovoRx, Inc.
RNXT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $6 | $6 | $4 | $3 |
| G&A Expenses | $5 | $6 | $6 | $3 |
| SG&A Expenses | $5 | $6 | $6 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $11 | $10 | $6 |
| Operating Income | -$11 | -$11 | -$10 | -$6 |
| % Margin | -25,511.6% | – | – | – |
| Other Income/Exp. Net | $2 | $1 | $0 | -$1 |
| Pre-Tax Income | -$9 | -$10 | -$10 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$10 | -$10 | -$6 |
| % Margin | -20,497.7% | – | – | – |
| EPS | -0.37 | -0.5 | -0.54 | -0.4 |
| % Growth | 26% | 7.4% | -35% | – |
| EPS Diluted | -0.37 | -0.5 | -0.54 | -0.4 |
| Weighted Avg Shares Out | 24 | 21 | 18 | 18 |
| Weighted Avg Shares Out Dil | 24 | 21 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$11 | -$10 | -$5 |
| % Margin | -25,511.6% | – | – | – |